InsidersTradesSigma
Total declarations
Companies
▲ Purchases (29 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
29
Disclosed sells
1
T+90 hit rate
31%
T+90 mean return
+2.7%
Across 13 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Biotech Target N V, Board Member / 10% Owner. Officer active across 4 companies, notably Esperion Therapeutics, Inc.. In total, 31 reports have been logged. Breakdown: 29 buys · 1 sell. Total volume traded: €49m. History available since 5 May 2021. The latest transaction was filed on 14 November 2024 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Biotech Target N V
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations31 total
1,279,820 shares@ US$0.66095.0% of flowCommon StockSEC:0000950170-24-128208:0
250,000 shares@ US$2.353.4% of flowCommon StockSEC:0000950170-24-042010:0
Canonical exit: 1 Jul 2024 (T+90)
150,000 shares@ US$4.46391.6% of flowCommon StockSEC:0000899243-23-019881:0
Canonical exit: 31 Dec 2023 (T+90)
200,000 shares@ US$5.26422.5% of flowCommon StockSEC:0000899243-23-018688:0
Canonical exit: 6 Dec 2023 (T+90)
4,255,319 shares@ US$0.4711.2% of flowCommon StockSEC:0000950170-23-033494:0
Canonical exit: 15 Oct 2023 (T+90)
500,000 shares@ US$5.06525.9% of flowCommon StockSEC:0000899243-23-005209:0
Canonical exit: 15 May 2023 (T+90)
150,000 shares@ US$5.29951.8% of flowCommon StockSEC:0000899243-23-002378:0
Canonical exit: 19 Apr 2023 (T+90)
200,000 shares@ US$5.8842.8% of flowCommon StockSEC:0000899243-22-039423:0
Canonical exit: 23 Mar 2023 (T+90)
300,000 shares@ US$5.96064.4% of flowCommon StockSEC:0000899243-22-036996:0
Canonical exit: 20 Feb 2023 (T+90)
250,000 shares@ US$4.62843.0% of flowCommon StockSEC:0000899243-22-034118:0
Canonical exit: 19 Jan 2023 (T+90)
250,000 shares@ US$4.3622.8% of flowCommon StockSEC:0000899243-22-034118:1
Canonical exit: 22 Jan 2023 (T+90)
168,422 shares@ US$3.70451.6% of flowCommon StockSEC:0000899243-22-033943:0
Canonical exit: 17 Jan 2023 (T+90)
8,733,538 shares@ US$10.0088.8% of flowCommon StockSEC:0000899243-22-030031:0
477,824 shares@ US$5.56923.7% of flowCommon StockSEC:0000899243-22-018984:0
Canonical exit: 16 Aug 2022 (T+90)
200,000 shares@ US$1.1811.8% of flowCommon StockSEC:0000899243-22-018544:0
Canonical exit: 14 Aug 2022 (T+90)
200,000 shares@ US$4.03595.6% of flowCommon StockSEC:0000899243-22-001433:0
Canonical exit: 6 Apr 2022 (T+90)
250,000 shares@ US$6.298613.0% of flowCommon StockSEC:0000899243-22-001316:0
Canonical exit: 5 Apr 2022 (T+90)
200,000 shares@ US$18.501612.9% of flowCommon StockSEC:0000899243-21-045703:0
Canonical exit: 17 Feb 2022 (T+90)
100,000 shares@ US$12.9451.2% of flowCommon StockSEC:0000899243-21-038590:0
Canonical exit: 28 Dec 2021 (T+90)
100,000 shares@ US$20.63967.0% of flowCommon StockSEC:0000899243-21-038368:0
Canonical exit: 27 Dec 2021 (T+90)
150,000 shares@ US$12.27521.7% of flowCommon StockSEC:0000899243-21-037557:0
Canonical exit: 21 Dec 2021 (T+90)
750,000 shares@ US$6.0040.0% of flowCommon StockSEC:0000899243-21-037292:0
Canonical exit: 20 Dec 2021 (T+90)
400,000 shares@ US$20.94228.2% of flowCommon StockSEC:0000899243-21-036543:0
Canonical exit: 15 Dec 2021 (T+90)
100,000 shares@ US$6.135.4% of flowCommon StockSEC:0000899243-21-036541:0
Canonical exit: 15 Dec 2021 (T+90)
80,000 shares@ US$6.99774.9% of flowCommon StockSEC:0000899243-21-030317:0
Canonical exit: 24 Oct 2021 (T+90)
25 of 31 declarations
About Biotech Target N V
BIOTECH TARGET N V is a declarant, and the primary role shown is Board Member / 10% Owner. The file contains 31 filings in total, and across the sampled recent filings from 2021-05-07 to 2024-11-18, the reported volumes are EUR 48210667 for buys and EUR 800666 for sells. The companies mentioned are Macrogenics INC, Molecular Templates, Inc., Radius Health, Inc. and Esperion Therapeutics, Inc.
